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Takashi Inozume1, Tomonori Yaguchi2, Junpei Furuta1, Kazutoshi Harada3, Yutaka Kawakami2 and
Shinji Shimada1Recently, T-cell immunoreceptor with Ig and ITIM domains (TIGIT) was reported as a candidate for novel
immune checkpoints. However, the impact of TIGIT on melanoma-specific cytotoxic T lymphocytes in the
effector phase remains unclear. In this study, we demonstrated that melanoma cells control antimelanoma
cytotoxic T lymphocyte responses via the TIGIT-CD155 interaction in the effector phase. TIGIT is an inhibitory
receptor expressed on T cells, and CD155 is one of the cognate ligands expressed on the tumor cells or antigen-
presenting cells. First, we confirmed that CD155 was constitutively expressed on melanoma cells. We then
demonstrated that CD155 on melanoma cells suppressed cytokine release from melanoma-specific cytotoxic
T lymphocytes via interaction with TIGIT. Overexpression of CD155 enhanced and its downregulation atten-
uated the suppressive effect. This suggested that antimelanoma cytotoxic T lymphocyte responses are
controlled not only by an imbalance in CD226 (an activating molecule that binds to CD155) and TIGIT
expression on T cells but also by the expression levels of CD155 on melanoma cells. In addition, the
co-blockade of TIGIT and PD-1 signals synergistically elicited a response of tumor-infiltrating lymphocytes on
autologous melanoma cells. These results suggest that the CD155-TIGIT interaction should be blocked for
enhancement of antimelanoma immune responses.
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The blockade of coinhibitory signals of T cells is a very
promising strategy to treat progressive tumors (Brahmer et al.,
2012; Hamid et al., 2013; Hodi et al., 2010; Robert et al.,
2011; Topalian et al., 2012; Wolchok et al., 2013). PD-1 is
a representative coinhibitory molecule that is upregulated in
activated cytotoxic T lymphocytes (CTLs) (Pardoll, 2012). The
cognate ligand PD-L1 is upregulated on various types of tu-
mor cells by stimulation with IFN-g, an essential cytokine for
antitumor immune responses (Palmer et al., 2008). Although
the interaction between PD-1 and PD-L1 is important for
maintaining self-tolerance, it also limits the antitumor T-cell
responses (Ahmadzadeh et al., 2009; Inozume et al., 2010).
In recent clinical trials, the blockade of the PD-1-PD-L1
interaction prolonged survival and induced marked clinical
responses in patients with progressive tumors (Brahmer et al.,
2012; Hamid et al., 2013; Topalian et al., 2012). Previously,
we attempted to identify novel IFN-g-inducible coinhibitory
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this study, we demonstrated that one of the candidate genes,
CD155, is an important coinhibitory molecule on mela-
noma cells. However, in contrast with PD-L1, CD155 was
constitutively expressed on melanoma cell lines and tissues.
CD155 has been reported to mediate activation of T cells
via CD226 or inhibition of T cells via T-cell immunor-
eceptor with Ig and ITIM domains (TIGIT) (Chan et al.,
2012). A recent report demonstrated the imbalance in
CD226 and TIGIT expression on tumor-infiltrating lympho-
cytes (TILs) in vivo, and this may negatively control anti-
melanoma T-cell response in tumor environment (Chauvin
et al., 2015). We found that CD155 constitutively
expressed on melanoma cells suppressed the activation of
melanoma-specific CTLs via interaction with TIGIT in the
effector phase. In addition, overexpression of CD155
enhanced and its downregulation attenuated the effect. This
finding implies that the expression levels of CD155 on
melanoma cells also control antimelanoma CTL responses.
Moreover, we found that CD155 and PD-L1 on melanoma
cells cooperatively suppressed the activation of human
melanoma-specific CTLs and TILs, even in the effector
phase. Our data strongly suggest that the CD155-TIGIT
interaction should be blocked for full activation of anti-
melanoma CTL responses.
RESULTS
Melanoma cells constitutively expressed CD155
To confirm CD155 expression on melanoma cells and other
tumor cell lines, we performed FACS analysis using the
anti-CD155 antibody. In contrast with PD-L1, CD155 wasestigative Dermatology. www.jidonline.org 255
Figure 1. Melanoma and other tumor cell lines constitutively expressed CD155. Six melanoma cell lines and other tumor cell lines were stained with
antihuman CD155 antibody. Line: isotype control; filled: CD155 staining. Specificity of the antibody used in the experiment was confirmed by staining for
transfectants (Figure 5a).
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Specificity of the antibody was confirmed by staining of the
CD155 transfectant (Figure 5a). In addition, we detected
constitutive CD155 expression on melanoma tissues
(Figure 2a). Some heterogeneity in intensities of staining was
observed between the samples; CD155 was uniformly
expressed on the membranes of melanoma cells. CD155
staining of three additional melanoma tissues and three mel-
anocytic nevus tissues is shown in Supplementary Figure S2
online. Compared with melanoma tissues, expression levels
of CD155 on nevus cells were very low. In our previous report,
CD155 was included in the list of candidates for IFN-g-
inducible immunosuppressive factors (Furuta et al., 2014), and
we could detect that the expression levels of CD155 onFigure 2. CD155 was constitutively expressed by human melanoma tissues and u
tissues were stained with the antihuman CD155 antibody (bottom panels) or isot
cultured in the presence or absence of rhIFN-g (1000 U/ml, 48 hours). Then, the
control; filled: CD155 staining of melanoma cells. MFI is mean fluorescence int
Journal of Investigative Dermatology (2016), Volume 136melanomacellswereupregulatedbyexogenous IFN-g in some
melanoma cell lines (Figure 2b and Supplementary Figure S1
online), on which the expression of IFN-g inducible immu-
nosuppressive factors was expected (Furuta et al., 2014).
Overexpression of CD155 on melanoma cells suppressed the
activation of melanoma-specific CTLs in the effector phase
To examine the effect of CD155 overexpression on CTL
activation, we performed a co-culture assay using melanoma
antigen recognized by T cells 1 (MART-1)-specific CTLs and
501Amel cells with or without CD155 gene transduction. To
assess the impact of CD155 on CTL activation, 501Amel cells
transduced with PD-L1 gene were also prepared as a control.
The PI, CD3þ, and MART-1-tetramerþ gated populations inpregulated on some melanoma cell lines by IFN-g stimulation. (a) Melanoma
ype control (top panels). Black scale bar ¼ 100 mm. (b) Melanoma cells were
surface expression of CD155 was quantified by FACS analysis. Line: isotype
ensity of CD155 staining.
Figure 3. Overexpression of CD155 on melanoma cells suppressed the activation of melanoma-specific T cells via interaction with TIGIT in the effector
phase. (a) MART-1-specific CTLs used in the experiment constitutively expressed PD-1, CD226, and TIGIT. PI, CD3þ, and MART-1 tetramerþ gated populations
are shown. (b) Tumor stimulation induced CD226 downregulation and TIGIT upregulation in the melanoma-specific, IFN-g-producing CTLs (bold line). MART-
1-specific CTLs were co-cultured with 526mel cells (Figure 2B) for 6 hours in the presence of brefeldin A, before extracellular and intracellular and staining.
CD3þ and CD8þ gated populations are shown. (c) MART-1-specific CTLs (bulk or CD8þ purified, 104) and a MART-1-reactive TIL (TIL1, 105) were co-cultured
with 501Amel cells transduced with mock or CD155 (105) for 48 hours. Activation of CTLs was assessed by cytokine release from T cells in culture supernatants.
These experiments were repeated three times and the representative examples are shown. (d) 526mel cells were transfected with siRNAs targeting CD155 and
control siRNA. After 72 hours of transfection, the expression levels of CD155 and HLA-A*0201 (control) were assessed by FACS analysis (top panel, line: isotype
control; filled: CD155 or HLA-A*0201 staining, MFI is mean fluorescence intensity of CD155 staining), and 526mel cells were co-cultured with MART-1-
specific CTLs (bulk) for 48 hours (E/S ¼ 104/105) (bottom panel). Activation of T cells was assessed by cytokine release from T cells in culture supernatants. These
experiments were repeated three times and the representative examples are shown. CTLs, cytotoxic T lymphocytes; FACS, fluorescence-activated cell sorter;
siRNA, small interfering RNA; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIL, tumor-infiltrating lymphocyte.
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Figure 4. T-cell suppression by
CD155 overexpressed on melanoma
cells was mediated by the interaction
between CD155 and TIGIT. (a)
Melanoma cell lines (105) were co-
cultured with MART-1-specific CTLs
(bulk, 104) in the presence of an anti-
TIGIT antibody (MBSA43,
eBioscience, 10 mg/ml). Activation of
CTLs was assessed by cytokine release
from T cells in culture supernatants.
(b) 501Amel cells were transduced
with retroviruses that encode
truncations of the carboxyl terminus of
CD155, and their recognition by
MART-1-specific CTLs (bulk) was
measured by cytokine release from T
cells in culture supernatants (E/S ¼
104/105). These experiments were
repeated three times and the
representative examples are shown.
CTLs, cytotoxic T lymphocytes; TIGIT,
T-cell immunoreceptor with Ig and
ITIM domains.
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expressed PD-1, CD226, and TIGIT (Figure 3a). First, we
could confirm the CD226-TIGIT imbalance on melanoma-
specific CTLs by tumor stimulation (Figure 3b). In the IFN-g-
producing population of the quadrants (bold line), the ratios of
PD-1þ and TIGITþ populations increased, whereas the ratio of
CD226þ CTLs decreased compared with the IFN-g-negative
population. Then, we performed the co-culture assay using
bulk and CD8þ-purified populations of the CTLs and a
cultured TIL that recognized the MART-1 antigen in an HLA-
A*0201-restricted manner (TIL 1), as responder cells. In all
cases, CTL activation was significantly suppressed by the
overexpression of CD155 on melanoma cells (Figure 3c) in
the effector phase. We could also detect the suppressive effect
of CD155 in a short-term killing assay (Supplementary
Figure S3 online). The suppressive effect of CD155 was
comparable with that of PD-L1. Then, we performed the co-
culture assay using 526mel cells transfected with small
interfering RNA (siRNA) targeting CD155. The efficiency and
specificity of CD155 knockdown are shown in Figure 3d (top
panel). CTL activation was significantly enhanced by CD155
downregulation (Figure 3d, bottom panel). We could obtain
similar results in the experiment using 501Amel cells
(Supplementary Figure S4 online). The addition of an anti-
CD155 antibody also significantly enhanced the CTL activa-
tion (Supplementary Figure S5 online). Taken together, CD155
on melanoma cells may work as an immunosuppressive
molecule at least in the effector phase. Moreover, we could
confirm that overexpression of CD155 on melanoma cells
suppressed the antimelanoma immune response in vivo
(Supplementary Figure S6a and b online).
CTL suppression by CD155 on melanoma cells was mediated
by a unidirectional signal from CD155 to TIGIT
To confirm that the suppressive effect of CD155 on mela-
noma cells was mediated by the CD155-TIGIT interaction,Journal of Investigative Dermatology (2016), Volume 136we performed a co-culture assay using the mock and CD155
transfectants in the presence of an anti-TIGIT blocking anti-
body. In this experiment, we used a commercial functional
grade antibody (MBSA43, eBioscience). Its blocking effect
was suggested in the previous report (Lozano et al., 2012).
CTL recognition was enhanced by the antibody in both cases.
This finding suggested that CD155 constitutively expressed
on melanoma cells could suppress the activation of CTLs via
interaction with TIGIT, and upregulation of CD155 enhanced
the suppressive effect (Figure 4a). To examine whether the
suppressive effect was mediated by direct ligation of TIGIT
by CD155 or mediated by subsequent cytokine release from
the melanoma cells, we constructed a truncation mutant of
CD155 and compared the suppressive effect with that of
the wild-type CD155. The suppressive effect was observed to
be similar in both the cells (Figure 4b). This result suggested
that CD155 on melanoma cells suppressed the melanoma-
specific T cells by direct interaction with TIGIT on T cells.
PD-L1 and CD155 synergistically suppressed activation of
MART-1-specific CTLs and a human melanoma TIL even in
the effector phase
PD-L1 is a representative T-cellesuppressive molecule,
upregulated on melanoma cells by IFN-g stimulation.
Therefore, we examined whether CD155 and PD-L1 syner-
gistically suppress the activation of CTLs, using double
transfectants (Figure 5a). In the co-culture assay, over-
expression of PD-L1 and CD155 independently suppressed
the activation of CTLs, and an additive effect was also
observed (Figure 5b). Then, we examined the effect of PD-1
and TIGIT signal on the reactivity of human melanoma TILs
against autologous melanoma cells in the effector phase
(Figure 6). We generated a pair of a TIL (TIL 2) and an autol-
ogous melanoma cell line (Mel 2) from a patient with mela-
noma. The TIL constitutively expressed PD-1, CD226, and
TIGIT (Figure 6a). Specifically, the autologous tumor-specific
Figure 5. CD155 and PD-L1 additively suppressed the activation of melanoma-specific T cells in the effector phase. (a) Expression levels of CD155 and PD-L1
on melanoma cells used in the experiment. The cells were stained with anti-CD155 and anti-PD-L1 antibodies. Line: isotype control; filled: CD155 staining. (b)
PD-L1 and CD155 overexpressed on melanoma cells additively suppressed the activation of melanoma-specific CTLs via interaction with each ligand. MART-1-
specific CTLs (bulk or CD8þ purified, 104) and a MART-1 reactive TIL (TIL1, 105) were co-cultured with 501Amel cells transduced with CD155, PD-L1, or both
(105). In some conditions, blocking antibodies for PD-L1 (MIH1, eBioscience, 10 mg/ml) and TIGIT (MBSA43, eBioscience, 10 mg/ml) were added. Activation of
T cells was assessed by cytokine released from T cells in the culture supernatants. These experiments were repeated three times and the representative examples
are shown. *P < 0.0001. CTLs, cytotoxic T lymphocytes; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIL, tumor-infiltrating lymphocyte.
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face CD8 and intracellular IFN-g staining after co-culture with
autologous melanoma cells) expressed high levels of PD-1,
CD226, and TIGIT (Figure 6a, bottom). In addition, the autol-
ogous melanoma cell line (Mel 2) constitutively expressed
CD155 and PD-L1, which were upregulated by IFN-g stimu-
lation (Figure 6b). In the co-culture assay, TIL activation was
slightly enhanced by the addition of an anti-TIGITor anti-PD-
L1 antibody alone, and the coaddition of these antibodies
synergistically enhanced activation of the TIL (Figure 6c and
Supplementary Figure S7 online). In vivo, we could also detect
upregulation of PD-1 and TIGITon melanoma TILs compared
with CD3þ cells in splenocytes (Supplementary Figure S6c).
This may also imply the necessity of co-blockade for the TIGIT
signal and the PD-1 signal in vivo.
DISCUSSION
T-cellemediated immune responses are usually regulated
by counterbalancing stimulatory and inhibitory signals(Pardoll, 2012). For example, CD28 (stimulatory) and CTLA-4
(inhibitory) control T-cell responses via ligation with the
common ligands CD80 and CD86 expressed on antigen-
presenting cells. In this study, we focused on CD155,
which was highly expressed on various tumor cells (Figure 1),
including melanoma cells (Figures 1 and 2) (Casado et al.,
2009); in some melanoma cell lines, it was upregulated by
IFN-g stimulation (Figure 2b). The CD226 (stimulatory)
(Iguchi-Manaka et al., 2008; Tahara-Hanaoka et al., 2005,
2006) and TIGIT (inhibitory) (Joller et al., 2011; Levin et al.,
2011; Stanietsky et al., 2009; Yu et al., 2009) receptors
control T-cell function through mechanisms analogous to
those of CD28-CTLA-4 interactions with CD80-CD86. Taken
together, CD155 has characteristics similar to PD-L1
(Figure 2), and one of the cognate receptors, TIGIT, has
characteristics similar to CTLA-4. CTLA-4, PD-1, and PD-L1
are the inhibitory molecules that have been clinically tar-
geted for enhancing antitumor T-cell responses, and the
blockade of these molecules has been shown to prolong thewww.jidonline.org 259
Figure 6. Co-blockade of PD-1 and TIGIT signals synergistically enhanced the antitumor response of a human TIL against autologous melanoma cells in the
effector phase. (a) An in vitro expanded human melanoma TIL used in the experiment (TIL2) constitutively expressed PD-1, CD226, and TIGIT. PI, CD3þ
populations (top), and CD8þ, IFN-gþ populations after co-culture with autologous melanoma cells for 6 hours in the presence of blefeldin A (bottom) are shown.
Line: isotype control. (b) The autologous melanoma cell line (Mel 2) constitutively expressed HLA-DR, PD-L1, and CD155, and was upregulated by IFN-g
stimulation (48 hours, 1,000 IU/ml). (c) TIL 2 (105) was co-cultured with Mel 2 cells (105) for 48 hours. In some conditions, blocking antibodies for HLA-A/B/C
(W6/32, eBioscience, 10 mg/ml), PD-L1 (MIH1, eBioscience, 10 mg/ml), and TIGIT (MBSA43, eBioscience, 10 mg/ml) were added. Activation of T cells was
assessed by cytokine release from the T cells in the culture supernatants. These experiments were repeated three times and the representative examples are
shown. TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TIL, tumor-infiltrating lymphocyte.
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260overall survival of patients with melanoma (Brahmer et al.,
2012; Hodi et al., 2010; Robert et al., 2011; Topalian
et al., 2012). Therefore, we examined the possibility that
the blockade of the CD155-TIGIT interaction may also
enhance the antimelanoma CTL responses in the effector
phase.
TIGIT is a member of the CD28 family, containing two
ITIM motifs (Chan et al., 2010). In vitro, TIGIT is able to
inhibit the cytotoxicity of natural killer cells (Stanietsky et al.,
2009) and activation of CD4þ T cells (Joller et al., 2011;
Lozano et al., 2012). In vivo, TIGIT ligation attenuates
experimental autoimmune diseases (collagen-induced
arthritis and experimental encephalitis models) (Joller et al.,
2011; Levin et al., 2011) and graft-versus-host disease (Seth
et al., 2011). Similar to that of CTLA-4, expression of TIGIT
is dynamically regulated, whereby TIGIT is not expressed on
steady-state T cells but is upregulated on the T-cell activation
(Joller et al., 2011; Lozano et al., 2012) and can bind toJournal of Investigative Dermatology (2016), Volume 136CD155 with much higher affinity than CD226 (Yu et al.,
2009). A recent report demonstrated that TIGIT is upregu-
lated on tumor-specific T cells infiltrating melanoma tumors
in a murine model (Goding et al., 2013). Another recent
report demonstrated that human melanoma TILs express
higher levels of TIGIT and lower levels of CD226 compared
with peripheral blood T cells (Chauvin et al., 2015). In this
article, we showed that TIGIT upregulation and CD226
downregulation of melanoma-specific CTLs were induced
by tumor stimulation (Figure 3b). These findings suggested
that an imbalance in CD226 and TIGIT expression is a
novel mechanism of T-cell suppression in the effector phase of
the antitumor CTL response. Moreover, in this study, we
demonstrated the possibility that the expression levels of
CD155 on melanoma cells also control the magnitude of
antimelanoma CTL responses (Figures 2 and 3). Taken
together, T-cell suppression via the CD155-TIGIT interaction
within the melanoma tumor microenvironment appears to be
T Inozume et al.
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T-cell responses.
Two recent reports showed the effect of TIGIT blockade
on antitumor immune responses. One report demonstrated
that coadministration of anti-PD-L1 and anti-TIGIT anti-
bodies eradicated a subcutaneously inoculated murine colon
carcinoma in vivo (Johnston et al., 2014). Another report
showed that TIGIT blockade alone or in combination with
PD-1 blockade increased the frequency of melanoma-
specific CTLs in vitro using a CTL induction assay (Chauvin
et al., 2015). However, the impact of TIGIT blockade on
antimelanoma CTL response in the effector phase has been
unclear. In this article, we clearly demonstrated that TIGIT
blockade alone or in combination with PD-1 blockade
enhanced the antimelanoma CTL response in the effector
phase using an in vitro co-culture assay of a melanoma
reactive human TIL and an autologous melanoma cell line
(Figure 6). This work should encourage the development
of humanized anti-TIGIT blocking antibodies for clinical use.
The blockade of CTLA-4 has been shown to significantly
improve the median overall survival of the patients with
melanoma in clinical trials (Hodi et al., 2010; Robert et al.,
2011). In addition, the blockade of PD-1 and PD-L1 has
been shown to induce durable tumor regression and prolong
disease stabilization (Brahmer et al., 2012; Topalian et al.,
2012). Moreover, a recent clinical trial clearly showed that
coadministration of anti-PD-1 and anti-CTLA-4 antibodies
resulted in a higher response rate (Wolchok et al., 2013). In
our experiment, the inhibitory effect of the CD155-TIGIT
interaction was comparable with that of the PD-L1-PD-1
interaction (Figures 3c and 5b) and they cooperatively sup-
pressed the antitumor T-cell responses (Figure 5b). A recent
report also demonstrated the synergistic effects of TIGIT and
PD-L1 co-blockade (Chauvin et al., 2015; Johnston et al.,
2014). Therefore, the blockade of the CD155-TIGIT interac-
tion could be a promising strategy to elicit antimelanoma
immune responses as a monotherapy or combination therapy
with PD-1-PD-L1 blockade.
Adoptive transfer of in vitro expanded TILs is one of the
most effective therapies for advanced melanoma (Rosenberg
and Dudley, 2009). Using a regimen of preparative host
lymphodepletion with cyclophosphamide and fludarabine
followed by infusion of cultured TIL, given with supportive
systemic IL-2, objective responsive rates of 49% to 72%
have been observed with some patients maintaining com-
plete responses beyond 10 years. These data suggest that
activation of TILs is very important for tumor rejection. Some
reports have shown that in a tumor environment, tumor-
specific CTLs selectively and constitutively expressed high
levels of PD-1 (Ahmadzadeh et al., 2009; Inozume et al.,
2010), and such CTLs regain strong antimelanoma re-
sponses if they are appropriately activated (Gros et al., 2014;
Inozume et al., 2010). TIL therapy is believed to activate such
CTLs in vitro culture, and anti-PD-1 antibody therapy is
thought to activate the CTLs in a tumor environment. How-
ever, the response rate of anti-PD-1 antibody therapy is still
less than that of TIL therapy. This implies the existence of
critical immune checkpoint other than the PD-1-PD-L1
interaction. In fact, we demonstrated that the co-blockade of
TIGIT and PD-L1 synergistically enhanced the antiautologoustumor response of a human TIL (Figure 6), as shown in a
murine model (Johnston et al., 2014). These findings highlight
the importance of identifying and characterizing novel im-
mune checkpoints to develop the more effective antitumor
immunotherapy.
In this study, we have identified CD155 on melanoma cells
as an immunosuppressive molecule. Similar to the blockade
of the PD-1-PD-L1 and CTLA-4-CD80 interactions, the
blockade of the CD155-TIGIT interaction would be another
immunotherapy for advanced melanoma.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of University of
Yamanashi. Written informed consent was obtained from all
subjects.
Cell lines
All human melanoma cell lines, except for Mel 2 and the RCC #1
cell line used in this study, were established at Surgery Branch,
National Cancer Institute, National Institutes of Health (Bethesda,
MD). Mel 2 was established as described previously (Inozume et al.,
2010). The 293GP, MDA231, and K562 lines were purchased from
ATCC (Manassas, VA).
Generation of cell lines with stable expression of human
CD155 and human PD-L1
Human melanoma cells lines were cultured in RPMI1640 (Grand
Island Biological, Grand Island, NY) supplemented with 10% fetal
bovine serum and antibiotics. To introduce genes into the cell lines,
the human CD155 gene and CD155 gene lacking a cytoplasmic
domain were cloned by reverse transcription PCR from the human
melanoma cell line 526mel. The genes were sequenced and subcl-
oned into the retroviral vector pQCXIP (Clontech, Mountain View,
CA). The plasmid encoding human PD-L1 was a gift from Dr Ken-
ichi Hanada (Surgery Branch, National Cancer Institute). Vesicular
stomatitis virus G protein-pseudotyped retrovirus was prepared by
transiently transfecting the 293GP cell line as described previously
by Wang et al. (2005). Melanoma tumor cell lines were then infected
with filtered cell-free viral supernatant in the presence of 8 mg/ml
polybrene and subsequently maintained in the selection medium
with 10 mg/ml puromycin (Sigma Aldrich Japan, Tokyo, Japan).
Retroviral transduction of peripheral blood lymphocytes
The plasmid encoding the HLA-A*0201-restricted, MART-1-specific
T-cell receptor was also a gift from Dr Ken-ichi Hanada (Johnson
et al., 2009). Peripheral blood lymphocytes from healthy donors
were stimulated with soluble OKT-3 (50 ng/ml; eBioscience, San
Diego, CA) and recombinant human IL-2 (300 IU/ml) for 2 days
before transduction was performed. The stimulated cells were added
to 24-well plates, initially coated with RetroNectin (10 mg/well in
400 ml of PBS; Takara Shuzo, Japan) and subsequently precoated
with retrovirus by spinoculation (2,000  g, 32 C, 2 hours). The
plates were then centrifuged at 1,000  g for 10 minutes and
incubated overnight at 37 C in a 5% CO2 incubator. This procedure
was repeated the next day, and the cells were split as necessary to
maintain the cell density of between 0.5 and 1  106 cells/ml.
In some experiments, purified CD8þ populations were used.
Purification of CD8þ T cells was performed by negative selection
columns as per the manufacturer’s recommendations (R&D Systems,
Minneapolis, MN). In brief, a monoclonal antibody (mAb) mixture
(Miltenyi Biotec K.K., Tokyo, Japan) was added to peripheral blood
lymphocytes transduced with the MART-1-specific T-cell receptor towww.jidonline.org 261
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262negatively select CD8þ T cells. The cells were added to the T-cell
subset column, incubated, and eluted with column buffer. The purity
of the recovered cells ranged from 90% to 95%.
In vitro expansion of human melanoma TILs
TILs were expanded as described previously (Inozume et al., 2010).
In brief, melanoma tumor digests were initiated in 2-ml wells con-
taining RPMI1640 supplemented with 10% human serum, antibi-
otics, and recombinant human IL-2 (6,000 IU/ml, Novartis, East
Hanover, NJ) in a humidified 37 C incubator with 5% CO2. Five
days after initiation, half of the media was aspirated from the wells
and replaced with a fresh complete medium and IL-2; this was
repeated every 2 to 3 days thereafter as needed.
Antibodies and reagents
Recombinant human IFN-g was purchased from R&D Systems
(Minneapolis, MN). The following mAbs, which are specific for
human antigens, were purchased from eBioscience: phycoerythrin
(PE)-conjugated antihuman CD3 (HIT3a), FITC-conjugated anti-
human CD4 (OKT-4), APC-conjugated antihuman CD8 (SK1),
functional grade antihuman PD-L1 (MIH1), PE-conjugated anti-
human IFN-g (4S.B3), functional grade antihuman TIGIT (MBSA43),
functional grade anti-HLA class I (W6/32), and functional grade
isotype control (P3). PE-conjugated antihuman CD155 (2H7CD155),
PE-conjugated antihuman PD-L1 (MIH1), PE-conjugated antihuman
TIGIT (MBSA43), PE-conjugated antihuman CD226 (11A8), and
isotype controls conjugated to PE were purchased from BioLegend
(San Diego, CA). Anti-CD155 (LS-B897) antibody and isotype con-
trol used for immunohistochemistry were purchased from LSBio
(Seattle, WA). The HLA-A*0201/MART-1:27-35 tetramer was pur-
chased from Medical and Biological Laboratories (Nagoya, Japan).
Flow cytometry analysis
In some experiments, the cells were treated with recombinant
human IFN (rhIFN)-g (1,000 U/ml, 48 hours) and washed before
staining. The cells were resuspended in staining buffer (PBS con-
taining 3% fetal bovine serum) and stained with fluorochrome-
conjugated antibodies. The stained cells were subsequently
washed in the staining buffer twice and briefly stained with propi-
dium iodide to exclude nonviable cells before analysis in a FACS-
Calibur flow cytometer (Becton Dickinson, San Jose, CA).
Intracellular staining of cultured T cells for the detection of IFN-g
production was performed by using a Cytofix/Cytoperm kit (BD
Bioscience, San Jose, CA) according to the product’s instructions.
Before fixation and extracellular staining, T cells were co-cultured
with melanoma cells (1  106 cells/well) in the presence of ble-
feldin A (GolgiPlug; BD Bioscience) at 37 C for 6 hours.
Cytokine release assay
Cultured tumor lines (105 cells/well) were used as stimulator cells.
Melanoma-specific T cells at 104e105 cells/well were added to the
tumor cells in a final volume of 200 ml and incubated for 48 hours.
In some experiments, anti-TIGIT mAb (MBSA43, eBioscience), anti-
PD-L1 mAb (MIH1, eBioscience), anti-HLA class I mAb (W6/32,
eBioscience), or isotype control (P3, eBioscience) was added at 10
mg/ml. Supernatants were assayed by ELISA for IFN-g (eBioscience).
siRNA knockdown of human CD155
Human-specific CD155 small-interfering RNA (Silencer Select
siRNA; siRNA IDs: s11601 and s11602) and negative control siRNA
were purchased from Ambion (Carlsbad, CA). 526mel cells were
seeded at a density of 2  105/ml in six-well plates and then
transfected with CD155 siRNA (100 nM) or negative control siRNAJournal of Investigative Dermatology (2016), Volume 136using a lipofectamine reagent (Invitrogen, Carlsbad, CA) in
antibiotic-free RPMI1640 supplemented with 10% fetal bovine
serum for 24 hours according to the manufacturer’s instructions.
Thereafter, the cells were transferred to a fresh medium. Knockdown
of the CD155 expression in the cells was confirmed by the flow
cytometry analysis of CD155 at 72 hours after transfection.
Immunohistochemistry
Sections of formalin-fixed, paraffin-embedded tissue were dried and
subsequently dewaxed and rehydrated. Endogenous peroxidase ac-
tivity was blocked by incubation with 0.3% hydrogen peroxide in
methanol. After antigen retrieval by boiling for 10 minutes in 10
mmol/l citrate buffer (pH 6.0), the tissue sections were incubated
overnight with antibodies. Then, the sections were incubated with a
horseradish peroxidase-conjugated secondary antibody. Immunore-
activity was detected using the LSAB Plus kit (Dako, Tokyo, Japan)
and counterstaining was performed using Mayer’s hematoxylin.
Statistical analysis
Student’s t-tests were used to evaluate significant differences in
enumeration assays. P values of less than 0.05 were considered
statistically significant.
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